• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A METHOD FOR PRODUCING METHYL ETHER OCTAPEPTIDES of the general formula I X-Arg-VaB-Tyr-lEe-HIs-Fro-Y-OMe, His (Dnp) -Y-OMe, where 1 is benzyloxycarbonyl; N02 nitro group; BzB is benzyl; Opr - dinitrophenyl; X, Y have the indicated values, cleave the dinitrophenyl protecting group by treatment with 2-mercaptoethanol, and then the o-O) tal protecting groups are removed by catalytic hydrogenolysis.
    公开号:SU1041030A3
    申请号:SU813226301
    申请日:1981-01-16
    公开日:1983-09-07
    发明作者:Ньеки Ольга；Кишфалуди Лайош；Карпати Эгон；Спорни Ласло
    申请人:Рихтер Гедеон Ведъесети Дъяр Рт (Инопредприятие)；
    IPC主号:
    专利说明:

    The invention relates to the preparation of new compounds, namely, methyl octapeptide ethers, and can be used in medicine. The known method of peptides half-life by cleaving the dinitrophenic protective group from the corresponding protected peptide in dimethylformamide under the action of 2-m captoethanol for 1.5-2.0 hours at room temperature fl. There is also known a method of removing protective groups in peptides by catalytic hydrogenolysis in an aqueous organic medium in the presence of 10-palladium on activated carbon 2 J. The purpose of the invention is to obtain new peptides with valuable pharmacological properties. This goal is achieved by the fact that according to the method of producing octapeptide methyl esters of general formula X-Arg-VaE-Tyr-1Pe-His-Pro-Y-OMe where X is Sar, hydroxyacetyl; Y - lEe, Thr (Me), Thr, AEa, from the methyl ester of a protected octapeptide of the general formula Z-Arg (N02) -VaB-Tyr (Bzl2) -lBeHis (Dnp) -Pro-Y-OMe, (Q where Z is benzyloxycarbonyl; N0 is a nitro group; BzE is benzyl; Dnp is dinitrophenyl; X and Y have the indicated meanings, the dinitrophenyl protective group is cleaved by treatment with 2-mercaptoethanol, and then the remaining protective groups are removed by catalytic hydrogenolysis. octapeptides of general formula (II) are obtained by known methods of peptide chemistry by stepwise increasing the peptide chain with using pentafluorophenyl esters of protected amino acids l. For protecting side functional groups, protecting groups are used that are stable under the conditions of acidolysis of the peptide bond for cleavage of protecting groups after completion of the peptide bond formation reaction. For the temporary protection of hydroxyl tyrosine, a benzyl group (BzF) is used for protection of the histidine imidazole ring - dinitrophenyl group (Dnp) and. for guan protection, the arginine idinogroup is a nitro group (NO2). These protective groups are resistant to the action of acids, as a result of which the t-butyloxycarbonyl group (BFB) used to protect o (.- amino groups in the peptide chain building process is cleaved off selectively without affecting the said protective groups. Preparation of new methyl ethers of octapeptides of the general formula (I) is illustrated by the examples given, where NOAA reduction is hydroxy acetic acid. Thin layer chromatography is carried out on plates using the following solvent systems: ° 1. Ethyl acetate: (pyridine-acetic acid that water is 20: 6: 11) 98: 2. 2. Ethyl acetate; (pyridine - acetic acid - water 20: 6: 11) 95: 5. 3. Ethyl acetate: (pyridine - acetic acid - water 20: 6: 11 ) 90:10. K. Ethyl acetate: (pyridine - acetic acid - water 20: 6: 11) 80:20. 5. Ethyl acetate: (pyridine - acetic acid - water 20: 6: 11) 70:30. 6. Ethyl acetate : (pyridine - acetic acid - water 20: 6: 11) 60:40. 7. and-ButanoN: acetic acid: water A: 1: 5 ... ... 8. n-Butanol: acetic acid: pyridine: water 30: 6: 20: 2. 9.n-Butanol: ethyl acetate-acetic acid: water 1: 1: 1: 1. 10. n-Butaethyl acetate:. (Pyridine acetic acid - water 20: 6: 11 75:25. Thin-layer chromatograms are displayed with ninhydrin or chlorotolidine solution with potassium iodide. Purification of the target products is carried out by the conventional method: 0.5 g peptide, yes in k ml of 0.01 M ammonium acetate solution is passed through a column containing 0.5 liters of carboxymethyl cellulose (CMC-52) and pre-equilibrated with a 0.01 M solution of ammonium acetate. The product is purified by gradient elution using 1.5 liters of 0.01. M solution of ammonium acetate and 1.5 liter of 0, M solution of ammonium acetate. 25 ml / h. Collect 10 ml fractions and detect with a LKB Uvl instrument to lyophilize the main fraction. Example: Methyl ether (Sar, I E) angiotensin 11. Step 1, Boc-Arg (N02) -VaErTyr (Bz IEe-His (Onp) -Pro-lEe-OMe. To 1.36 g of f7.5 mmol of isoleucine methyl ester hydrochloride in chloroform, 1.05 ml of triethylamine and 1.90 g (5 mmol) of PEB-tfluorophenyl ether were added. The mixture is stirred for 30 minutes at constant pH and extracted with water, aqueous citric acid solution, and water. The organic layer is dried over sodium sulfate and evaporated. The rest of the protected dipepty (, 8) was dissolved in 5 ml of BH. hydrochloric acid in dioxane. After 15 minutes, the solution was diluted with 20 ml without aqueous ether and evaporated. The rest of the dipeptide hydrochloride (R:, 0.46) was dissolved in 30 ml of chloroform, triethylamine was added to pH B and 4.36 g (7.5 mmol) of BOC-histidine pentafluorophenyl ester. After 1 hour, 0, EO3 ml of N, M-dimethylaminoethylamine was added to the solution, and after 15 minutes, the mixture was extracted with aqueous citric acid solution, saturated sodium chloride solution, 1N. hydrochloric acid solution, aqueous sodium bicarbonate solution and water. The organic phase is dried over sodium sulfate and evaporated. The resulting protected tripeptide (Rr 0.45) was dissolved in 10 ml of 8N without purification. hydrochloric acid solution in dioxane. After 15 minutes, the solution is diluted with anhydrous ether, and the free tripeptide hydrochloride that precipitates is filtered off, washed with ether, and dissolved in 15 ml of dimethylformamide. Triethylamine was added to the resulting solution until pH & and 2, Lg (6 mmol) of BOC-isoleucine pentafluorophenyl ether. The mixture is kept for 30 minutes at constant pH and evaporated. The residue is dissolved in ethyl acetate. The solution is washed with a 10% citric acid aqueous solution, 1N. hydrochloric acid solution, water, dried over sodium sulfate and evaporated. The residue is triturated with a mixture of ether - hexane (1: 9). and filtered. The obtained protected tetrapeptide (R - 0.31) of ranic acid in dioxane. After 15 minutes, anhydrous ether was added and the hydrochloride of the free tetrapeptide precipitated in the precipitate was filtered off. The resulting tetrapeptide (P; 0.38) is dissolved in a mixture of 10 ml of dimethylformamide and 20 ml of chloroform, triethylamine is added to pH 8 and 2.96 g (5.5 mmol) of pentafluorophenyl ester BOC-0-benzyl- Tyrosine. The mixture was kept at a constant pH of 15 minutes and evaporated. The residue was dissolved in ethyl acetate, 0.22 ml of M, M-dimethylaminoethylamine was added and, after 10 minutes, washed with aqueous citric acid solution, 1N. hydrochloric acid solution and. water The organic phase is dried over sodium sulfate and evaporated. The residue is triturated with anhydrous ether and filtered. The resulting protected pentapeptide (, 52) is dissolved in 10 ml of 8N. hydrochloric acid solution in dioxane, anhydrous ether is added after 15 minutes and the precipitated precipitate is filtered off and washed with ether. The resulting free pentapeptide hydrochloride (, 8) is dissolved in 20 ml of dimethylformamide, triethylamine is added to pH 8 and 2.3 g (6 mmol) of BOC-pentafluorophenyl BOC-valine ester. The mixture was kept at a constant pH of 1 h and evaporated. The residue was dissolved in chloroform and the resulting solution was washed with 10% aqueous citric acid solution, 1N. hydrochloric acid solution, water, dried over sodium sulfate and evaporated. The residue is triturated with anhydrous ether and filtered. The resulting protected hexapeptide (, 3) is dissolved in 8N. a solution of hydrochloric acid in dioxane, anhydrous ether is added after 15 minutes, and the precipitated precipitate is filtered off and washed with ether. The resulting free hexapeptide hydrochloride is dissolved in 15 ml of dimethylformamide, triethylamine is added to pH 8 and 2.6 g (6 mmol) of PCB-M6-nitroarginine. The mixture was kept at a constant pH for 30 minutes, kS ml of chloroform was added, washed with 1N hydrochloric acid and water, dried over sodium sulfate and evaporated. The residue is triturated with ethyl acetate and filtered.
    3.3 g of Boc-Arg-lhlOg) Vat-Tyg- (Bz e) - I Ee-H I s (Dnp) -Pro-G fce: OMe are obtained (yield 51% of the theoretical calculated for the starting compound Pentafluorophenyl ether BOC -prod lin). , 37.
    Step 2. Z-Sar-Arg (N02) -VatTyr (B2E) -lfe-Hls (Dnp) -Pro-l Her-OMe.
    3.3 g (2.5 mmol) of Boc-Arg (N02) -VaE-Tyr (BzE) L-lEeHis (Dnp) -Pro-lpe ethyl ester ethyl acetate were dissolved in 15 ml. 8 n. a solution of hydrochloric acid in dioxane, anhydrous ether is added after 20 minutes, the precipitated product is filtered and washed with ether. The resulting free heptapeptide hydrochloride (, 7) is dissolved in 15 ml of dimethylformamide, triethylamine is added to pH 8 and 2 g (6 mmol of Z-Sar pentafluorophenyl ester. The mixture is maintained at constant pH for 30 minutes, 5 ml of chloroform is added, washed 1 The hydrochloric acid solution and water are dried over sodium sulfate and evaporated. The residue is triturated with ethanol and filtered.
    Obtain 3.17 g (89 from theoretical.) Protected octapeptide Z-Sar-Arg (MO) -Val-Tyr {Bz1) -lJeHis (Dnp) -Pro-l 1e-OMe. M.p. 1972Q9 ° C, RpO, 82.
    Stage 3. Removal of protective groups. 2.59 g (1.83 mmol) of Z-Sar-A.rgCNO Val-Tyr (Bzi) -lle-His (Dnp) -Pro-neOMe is dissolved in 5 ml of dimethylformamide and A is added to the solution, 6 ml 2 - mercaptoethanol. The mixture was stirred for 1 hour and anhydrous ether was added. The precipitate is filtered off. Receive 2, About g (87% of theoretical) Z-Sar-Arg (N02) -Val-, (BzO-Ne-His-Pro-Me-OMe (
    The product was dissolved in ml of a mixture of methanol-acetic acid water 5: 1: 1, 1.0 g of 10% palladium on activated carbon was added and hydrogen was passed through the solution for 20 hours with vigorous stirring. Then the catalyst is filtered off, the filtrate is evaporated Ostoato. To mix with aqueous ethanol and evaporated. The operation is repeated several times. The residue is then triturated with anhydrous ether, filtered and dried. .
    1.5b g (98% of theory) of methyl ester of (Sar, Ile) -angiotensin 11 is obtained. The product is purified as described above. The final product has the following characteristics:, 19; , 59; Rjl.0.38; Ej.en (, 9): 1.00 Amino acid analysis: Pro 1.07 (1) Val 1.9 (1); 0.8 0.8 (1); His 1.03fl) Arg 1.0 (1); Me 1.87 (2); Sar 1.0 (1)
    P p and M e p 2. Methyl ether (OGly, I 1e) -angiotensin 11.
    Step 1. Z-OG y-Arg (NO, 2) -ValTyr (Bz1) -M e-HIs (Dnp) -Pro-11e-OMe. 5 1.5 g (0.8 mmol) of Boc-.Arg (N02) .Val-Tyr (Bzl) -lle-His (Dnp) -Pro-lle-OMe (e.g. 1, step 1) is dissolved in 6 ml 8 n. hydrochloric acid solution in dioxane, after 20 minutes 0 anhydrous ether is added, the precipitated product is filtered off. The resulting chloro, free heptapeptide hydrate (R g of BO, 7) is dissolved in 10. ml of dimethylformamide, triethylamine is added to pH 5 and 0, A6 g (1.17 mmol) of Z-OGly pentafluorophenyl ester. After 30 minutes, 30 ml of chloroform is added to the mixture, washed with 10% aqueous citric acid solution, 1N. hydrochloric acid solution 0 and water, dried over sodium sulfate and evaporated.
    Obtain 1.05 g (93% of theoretical.) Z-OG1y-Arg (NOi) -Val-Tyr (Bzl) lle-His (Dnp) -Pro-lle-OMe; M.p. .2.
    Stage 2. Removal of protective groups. 1,05 t (0,7 mmol) Z-OGly-Arg (N02) Va1-Tug (Bz G) - And e-H is (Dnp) -Pro-1Ie-OMe is dissolved in 5 ml of dimethylformamide, Q to the solution are 2.3. ml of 2-mercaptoethanol, anhydrous ether is added after 2 hours, the precipitated product is filtered off and washed with ether. Obtain 0.85 g (85% of theoretical) Z-OGly-Arg (N02) (Bzl) Me-His-Pro-lle-OMe,), 0.75 g (0.6 mmol) of this product is dissolved in 20 ml of methanol acetic acid-water (5: 1: 1) j mixture was added 0.8 g of 10% Nalladi on activated charcoal and through a solution for 18 hours while intensive; stirring, let in hydrogen. Then the catalyst is filtered off, the filtrate is heated. The residue is mixed with water, ethanol and evaporated. The operation is repeated several times. Then the residue is triturated with. anhydrous ether, filtered and dried. 7. Receive / O, g (82 from theoretical) methyl ester. (OGly (l 1-th angiotensin 11, which is purified as described above. The final product has the following characteristics:,, 72; .Rj, 60. Amino acid analysis: Pro 1.0 (Val 1.0 (1); Me 1.7 (2); Ture 0.88 (His 1.02 (1); Arg 0.96 (1). P p and M ep 3. Methyl ether (Sar, Thb (Me)) - angiotesin 11. Step 1. Z-Sar-Arg (NO2) -Va1Tyr (Bz1) -1 1e-H is (Dnp) -Pro-Thr (Me) -O 0.68 g (, 5 mmol) of methyl, 0-ytyl-threonine ester is dissolved in 10 ml of chloroform and 2.28 g (6 mmol) of BOC-proline pentaftrphenyl ether are added. The solution is kept at a constant pH of 8 minutes and evaporated. The residue is dissolved Yu in ethyl acetate, 0.22 ml of N, N-dimethyl aminoethylamine is added, and after 15 minutes, it is washed with an aqueous solution of lemon nby acid, saturated sodium chloride solution, 1N hydrochloric acid and water, dried over sodium sulfate, sodium fate and evaporated The resulting protected dipeptide (, 76j was dissolved in 3 ml of 8N hydrochloric acid solution in dioxane. After 15 minutes, anhydrous ether was added and evaporated. The resulting bodon dipeptide hydrochloride (, 18) is dissolved in 10 ml of dimethylformamide, triethylamine is added to pH and 2.95 (5 mmol) of BOC-N dinitrophenyl-histidine pentafluorophenyl ester. The solution was incubated for 30 minutes at pH 8 and evaporated, and the residue was dissolved in et acetate. 0.11 M, N-dimethylaminoethylamine is added to the solution, after 10 minutes, washed with 10% aqueous citric acid solution, saturated sodium chloride with water and water, dried over sodium sulfate and evaporated. The obtained protected tripeptide (, 3) is dissolved in 10 dimethyl fluoride, amide, triethyl amide N 8 and 2.0 g (5 mmol) of pentafluorophenyl phenyl BOC-isoleucine are added, and the pH is maintained for 30 minutes. 8 and evaporated. The residue is dissolved in ethyl acetate. The solution is washed, dried and evaporated. The residue is triturated with a mixture of ether - hexane 3i7 and filtered. The resulting tetrapeptide (, 28), ..., is dissolved in 7 ml 8 n. hydrochloric acid solution in dioxane. After 15 minutes, anhydrous was added; the ether, the precipitated product was filtered and washed with ether. The product obtained (27) is dissolved in 10 liters of dimethylformamide, triethylamine is added to pH 8 and 2.7 g (5 mmol) of pentafluorophenyl. BOC-O.-benzyl-tyrosine ester, incubated for 30 minutes at pH 8, evaporated, the residue is dissolved in ethyl acetate. To the resulting solution was added 0.11 ml of N, N-dimethylethylamine, and after 15 minutes, it was washed with an aqueous solution of citric acid, a saturated solution of sodium chloride and water, dried over sodium sulfate and evaporated. The resulting protected pentapeptide (, 51) ra-. washed with anhydrous ether, filtered and dissolved in 5 ml 8 n. a solution of hydrochloric acid in dioxane, anhydrous ether is added after 15 minutes, the precipitated product is filtered off, washed with ether. The resulting free pentapeptide hydrochloride (, 48) is dissolved in 20 ml of dimethylformamide, triethylamine is added to pH 8 and 1.9 g (9 mmol) of WOK-valine pentafluorophenyl ether. The solution is kept at pH 8 for 30 minutes, evaporated, the residue is dissolved in chloroform, washed, dried and evaporated. The residue is triturated with anhydrous ether and filtered. The resulting protected hexapeptide (K-0, kh) is dissolved in 10 ml of 8N. a solution of hydrochloric acid in dioxane and anhydrous ether is added after 15 minutes, the precipitated product is filtered and washed with ether. The resulting free hexapeptide hydrochloride (, Pb) is dissolved in 15 ml of dimethylformamide, triethylamine is added to pH 8 and 2.25 g (5 mmol) of BOK-N -nitroarginine pentafluorophenyl ether. The solution is allowed to stand at pH 8 for 1 h, diluted with chloroform and treated as described above. The residue obtained is triturated with ethanol and filtered. 3.3 g (91 of the theoretical yield calculated for threonine) Boc-ArgCN02) -Val-Tyr (BzO-lleHis (Dnp) -Pro-Thr {Me) -OMe are obtained. M.p. 188193 ° С:. .87. 193 ° C; , | 8; ., 87. 1.95 g (1.5 mmo.b) of the above protected heptapeptide methyl ester is dissolved in 10 ml of 8N. a solution of hydrochloric acid in dioxane and after 20 minutes precipitate the product by adding anhydrous ether, which is filtered off and washed with ether. The resulting free heptapeptide hydrochloride, 20;) is dissolved in 15 ml of dimethylformamide, triethylamine is added to pH 8 and 0.87 g (2.25 mmol) of Z-Sar pentafluorophenyl ether. The solution is kept at pH 8 for 1 hour and diluted with chloroform and processed as described above. Obtain 1.85 g (87 from theoretically KQro) methyl ester of the protected octapeptide Z-Sar-Arg (N62) -Val-Tug (Bzl) -lle-His (Dnp) -Pro-Thr (Me) -OMe, Tpl . 202-208 ° C; ,20; , 86 Stage 2, Removal of protecting groups 1.85 g (1, mmol) Z-Sar-Arq (N02 (Bz) -Me-His (Dnp) -Pro-hr (M OMe dissolved in ml ml dimethylforma 2.6 ml of 2-mercaptoethanol is added to the solution, anhydrous ether is added after 1 h. The precipitated product is filtered off and washed with ether to obtain 1.6 g of Z-Sar-Arg (N02) -ValTyr (Bzl) -Me-His- Pro-Thr (Me) -OMe, (, 52), The resulting product was diluted with 30 ml of a mixture of methanol - acetic acid - water (5: 1: 1), the catalyst was added (10% palladium on activated carbon ) and with vigorous stirring, hydrogen is passed in for 30 hours. Then the catalyst is filtered off, the filtrate The residue is triturated with ether: ethanol (2: 1) and filtered to give 0.98 g (83% of theory) of methyl ester (Zag, Thb (Me)) -angiotensin 11, which is purified as described above. the product has the following characteristics:, 29yfvf 0.55;, 27., Amino acid analysis: His 1.03 (Arg 0.95 (1); lie 0.93 (D; Pro 1.03 (1); Val 1.15 (1 ); tie 1.03 (D Tyr 0.9 (1); Sar 1.0 (1). Example. Methyl ether (OGly, Thr (Me)) -angiotensin 1 Stage 1. Z-OGly-Arg (N02) (Bz1) -M e-H i s (Dnp) -Thr (Me) -OMe. 0.62 g (0.7 mmol) of Boc-Arg (NOTj Va 1 -Tyr (Bz 1) –f 1 eH I s (Dnp); Tig (Me) -OMe. (Example 3, stage 1) is dissolved in 4 ml of 8 and, a solution of hydrochloric acid in dioxane and after 13 min, tell the product by adding anhydrous ether, filter and wash with ether. The resulting free heptapeptide hydrochloride (, 35) is dissolved in 10 ml of dimethylformamide, triethylamine is added to pH 8 and 0.8 g (2 mmol) of Z-OGly pentafluorophenyl ether. The solution is kept for 1 hour at pH 8, diluted with 30 ml of chloroform and treated as described above. The residue is triturated with ether: ethanol (9: 1) and filtered. 0.60 g (90 from the theoretical) methyl ester of the protected octapeptide Z-OG1y-Arg (N02) -ValTug (Bz) -11e-H is (Dnp) -Pro-Thr (Me) -OMe. TH PL. 158 -162 ° C; 4i. Step 2. Removal of protecting groups g, 6 r. (Q, k2 mmol) Z-OGly-Arg (N02) Val-T: yr (Bz) -l le-H is (Dnp ) -Pro-Thr (Me) OMe was dissolved in 2 ml of dimethylformamide, 1.2 ml of 2-mercaptoethanol was added to the solution, anhydrous ether was added after 1 h, the precipitated product was filtered ,. solution nt in methanol -. The solution is treated with activated carbon, filtered and evaporated. The residue is triturated with ether and filtered. 0.6 g of Z-OG1y-Arg (Mog) -Va1-Tug (6z1) -11еHis-Thr (Me) -OMe., L6; 52 The product is dissolved in 25 ml of a mixture of methanol-acetic acid and water (5: 1: 1), 0.3 g of 10-palladium on activated carbon is added and, with vigorous stirring, hydrogen is passed through for 17 h. Then the catalyst is filtered off, the filtrate is evaporated. The residue is mixed with aqueous ethanol and evaporated. The operation is repeated several times. 0.32 g (91% of theoretical) of methyl (OGly, A1a) -angiotensin 11 methyl ester is obtained, which purifies as described above. The final product has the following characteristics:, 22; pf 0.73; 56. Amino acid analysis: Thr 0.02- (1) Pro 1.03 (1); Val 1.0 (1); His 1.0 (l) Arg 1.0 (1). P p and M e p 5. Methyl ether (Ogly, Thr) -angiotensin 11. Step 1. Fo-Arg (NO2) -Val-Thug (BzI) Ile-His (Dnp) -Pro-Thr-OMe. g (20 mmol) of O-adethyl-tyrosine hydrochloride methyl ester is dissolved in 50 ml of chloroform, 2.3 ml (20 mmol) of triethylamine 11G per and .3.8 g (10 mmol) of BOC-proline pentafluorophenyl ether are added. The solution is maintained at a constant pH of 1 hour and is treated as described above. The resulting protected dipeptide (, 77) is dissolved in 20 ml 8 n. a solution of hydrochloric acid in dioxane, anhydrous ether is added after 15 min, the precipitated product is filtered off and washed with ether. The valuable product (2) is dissolved in 30 ml of chloroform, three is added; ethylamine to pH 8 and C, 7 g (8 mmol) of BOK-P dinitrophenyl-histidine pentafluorophenyl ether. The solution is incubated for 1 h at pH 8 and treated as described above. The residual protected tripeptide (, 7) is dissolved in 20 ml of 8N. hydrochloric acid solution in dioxane and after 15 minutes the product is precipitated by adding anhydrous ether. The resulting free tripeptide chlorohydrate (R.; 0.23) is dissolved in 20 ml of a mixture of chloroform - dimethylformamide (5: 0; triethylamine is added to pH 8 and 0 g (10 mmol) of pentafluorophenyl ether BOC-isoleucine. The solution is kept for 30 The residue is triturated with hexane and filtered. The resulting protected tetrapeptide (,) is dissolved in 15 ml of 8 and a solution of hydrochloric acid in dioxane and the product is precipitated by anhydrous ether after 15 minutes. The resulting free tetrape hydrochloride (Rt-0.25) is dissolved in 30 ml of dimethylformamide, is triethylamine to pH 8 and 2.05 g (3.8 mmol) of 0-benzyl-tyrosine pentafluorophenyl ester. The solution is kept for 30 minutes at pH 8, evaporated, the residue is dissolved in ethyl acetate. To the resulting solution is added 0.11 ml of H, M-dimethylaminoethylamine and the solution is treated after 15 minutes D. The residue is triturated with anhydrous ether and filtered off. The resulting protected pentapeptide (, 57) is placed in 10 ml of 8N solution of strong acid in dioxane. After 15 min, the product is precipitated by adding anhydrous ether, effluent and washed with ether ... j The resulting product (, 27) is dissolved in 20 ml of dimethylformamide, triethylamine is added to pH 8 and 1 ~ 75 g (4.5 mmol) of pentafluorophenyl O12 th ether BOC-valine. The solution is incubated for 1 h at pM 8 and evaporated. The residue is dissolved in chloroform and the solution is treated. The residue is triturated with ether, filtered and washed with ether. The resulting protected hexapeptide) is dissolved in 8 ml of 8 and. hydrochloric acid solution in dioxane, the product is precipitated after 15 min by adding anhydrous ether. the product is filtered off, washed with ether. The free hexyapeptide hydrochloride obtained, (, 23) is dissolved in 20 ml of dimethylformamide, triethylamine is added to pH 8 and 1.8 g of C mmol) BOC-M-nitroarginine pentafluorophenyl ester. The solution is kept for 1 h at rH 8, evaporated, the residue is dissolved in chloroform, the solution is treated, dried and evaporated. The residue is triturated with a mixture of ether - ethanol), filtered and washed with the above mixture. 2.7 g (26% of the theoretical yield calculated on histidine) are obtained. Boc-Arg (NOa) -Va 1-Tug (Bzl) - Me-H i S (Opr) Pro-Thr-OMe. M.p. 190-195 ° C (decomposition); 47 Stage 2. Z-OGlY-Arg (N02) -Va1Tug (Bz1) -M e-H i s (Dnp) -Pgo-Thr-OMe. 1.7 g (1, t mmol) of Bos-Agde (1 -Tyr (Bzl) -l le-His (Dnp) -Pro-Thr-OMe is dissolved in TO ml of 8 n solution. SALT. Acid in dioxane after 15 min, the product is precipitated by adding anhydrous ether. The product is filtered and washed with ether. The resulting free heptapeptide hydrochloride (, 21) is dissolved in 20 ml of dimethylformamide, triethylamine is added to pH 8 and 0.82 g (2.1 mmol) of pentafluorophenyl ether Z-OGly. The solution is kept at pH.8 for 30 minutes, diluted with lO ml of chloroform, washed with 1N hydrochloric acid and water, dried, and evaporated. The residue is triturated with anhydrous ether and o 1.6 g (87 from the theoretical) methyl ester of the protected octapeptide Z-OG1y-Arg (NO2) Val-Tyr (Bzl) -lle-His (Dnp) -Pgo-Thr OMe are obtained. mp. 188-194 ° C; 48. Stage 3. Removal of protecting groups. 1.6 g (1.2 mmol) 1-5ag-2-OC1yArg (N02) -Val-Tyr (BzlJ-lle-His (Dnp) P .ro- Thr-OMe is dissolved in 5 ml of dimethyl
    13
    : Tilformamide, add 2 ml of mercaptoethanol. After 1 h, the product is precipitated by adding anhydrous ether. The product is filtered and washed with ether, dissolved in methanol and precipitated by the addition of ether.
    Half of 1.3 g (from theoretical) Z-OGly-Arg (N02) -Val-Tyr (Bzl) Ue-Hls-Pro-Thr-OMe. , 35; Y --- 0.72.
    The product obtained is dissolved in methanol-acetic acid water (5: 1: 1), 0.6 g of 10% palladium on activated carbon is added and, with vigorous stirring, hydrogen is passed through for 17 hours. Then the catalyst is filtered off, the filtrate is evaporated. The residue is mixed with aqueous ethanol and evaporated. The operation is repeated several times. The residue is triturated with ether, filtered and washed with ether.
    Half of 0.6 g of methyl (OGly, Thb) -angiotensin 11, which is purified as described above.
    The final product has the following characteristics:, 22; , 73;
    ..56, -,
    Amino acid analysis: Thr 0.92 (1 Pro 1.03 (1); Va 1.0 (1); Ile1.5 (1) Tyr 0.7 (1); His 1.0 (1) i Arg 1 , 0 (1)
    P p and M e p 6, Methyl ether (Sar, Ala) -angiotensin 11.
    Step 1. Z-Sar-Arg (N02) -Va1Tug (Vn1) -1le-His (Dnp) -Pro-Ala-OMe.
    0.7 g (5 mmol) of alanine methyl ester hydrochloride is dissolved in 20 m of chloroform, 0.7 ml of triethylamine and 1.1 g (3 mmol) of BOC-proline pentafluorophenyl ether are added. The solution is maintained at a constant pH for 30 minutes and is processed as described, but above. The obtained protected dipeptide (, 6l) j is dissolved in 5 ml of 8N. solution of hydrochloric acid in dioxane, after 10 minutes, diluted with anhydrous ether and evaporated. The free dipeptide hydrochloride obtained (Rf-0.32) is dissolved in 20 ml of chloroform, triethylamine is added to pH 8 and 2.7 g (5 mmol) of BOC-N dinitrophenylhistidine pentafluorophenyl ether. The solution is kept at pH 8 for 1 hour, 0.33 ml of H, M is added, and dimethylaminoethylamine is added and, after 15 minutes, it is treated, dried and evaporated. The resulting protected tripeptide (, 27) is dissolved in 10 ml.
    030I
    8 n. hydrochloric acid solution in dioxane, after 15 minutes the product is precipitated by the addition of anhydrous ether. The resulting hldrgidrat free tr.epipn
    tide (, k8) is filtered off, washed with ether and dissolved in a mixture of chloroform - dimethylfrmamide (2: -1), triethylamine is added to pH 8 and 2, k g, (6 mmol) of pentafluorophenyl
    ester sideways isoleucine. The solution is kept for 30 minutes at pH 8 and evaporated. The residue is dissolved in ethyl acetate and the resulting solution is treated as described above, dried and evaporated.
    5 The residue was triturated with etherhexane (1: 9) and filtered. According to „/ (2)
    luchenny protected tetrapeptide (R ..
     0.29) is dissolved in 10 ml. 8 n. hydrochloric acid solution in dioxane and
    0 after 10 minutes, the product is precipitated by the addition of anhydrous ether. The resulting free tetrapeptide hydrochloride (, 67) is filtered off, washed with ether, dissolved in chloroform-dimethylformamide, (2: 1), added to a solution of triethylamine to pH 8 and 1.78 g (3.3 mmol) of pentafluorophenyl ether BOC- 0-benzyl tyrosine. The solution is kept
    15 min at pH 8 and evaporated. The residue is dissolved in ethyl acetate and the solution is treated, dried and evaporated. The residue is triturated with anhydrous ether and filtered. The resulting protected pentapeptide (, 33) is dissolved in 10 ml of 8N. hydrochloric acid solution in dioxane and after 10 minutes the product is precipitated by the addition of anhydrous ether. The resulting hydrochloride
    the free pentapeptide is filtered and dissolved in 20 ml of dimethylformamide, triethylamine is added to pH 8 and 1.55 g (mmol) of pentafluoro. BOC-valine phenyl ester. The solution is kept for 1 hour at pH and evaporated. The residue is dissolved in chlorofome and the solution is treated dried and evaporated. The residue is triturated with anhydrous ether and filtered. The resulting protected hexapeptide (Rf |
     0.35) is dissolved in 8 ml of 8N. hydrochloric acid solution in dioxane and after 20 minutes the product is precipitated by the addition of anhydrous ether. The resulting chlorine hydrate of free hexaptoide
    5 (, 75) is filtered off, washed with ether, dissolved in 20 ml of dimethylformamide, triethylamine is added to pH 8 and 2.6 g. (6 mmol) of BOK-N -HHTpoaprMHrt pentafluorine 151, the solution is kept for 1 hour at pH 8, dilute with 60 ml of chloroform, treat, dry and evaporate. The residue is triturated with a mixture of ethanol - ether {1: 3) is filtered off and washed. Polumeny protected hexapeptide. (, 35) was dissolved in 10 ml of 8N. After a 15-minute solution of hydrochloric acid in the dioxane, the product is precipitated by adding anhydrous ether. The resulting free heptapeptide hydrochloride (0.15) is filtered, washed with ether, dissolved in 20 ml of dime formamide, triethylamine is added to pH 8 and 1.27 g (mmol) of Z-Sar pentafluorophenyl ether. The solution is kept for 15 minutes at pH 8 diluted with 60 ml of chloroform and treated, dried and evaporated. The residue is triturated with 25 ml of ethanol, filtered and washed with ethanol. 1.37 g are obtained (33% of the theoretical yield calculated for Proline Z-Sar-Arg ( N02) -Val-Tyr. (Bzl.) -MeHis (Dnp) -Pro-Ala-OMe. Mp 192-19b, 70. Step 2. Removal of protective groups 1.37 g (1 mmol) of Z-Sar -Arg (N02) Val-Tyr (8zl) -lle-His (Dnp) -Pro-AlaOMe Dissolve in 3 ml of dimethylformamide, add 1, 9 ml of 2-mercaptoethanol and add aqueous ester after 1 h. The precipitated product is filtered off and washed with ether to obtain 1.2 g (99% of theoretical) Z-Sar- Arg (N02) -Va} -Tyr (Bz Me-His-Pro-Ala-OMe (, 20). The resulting product is dissolved in 20 ml of a mixture of methanol - acetic acid - water (5: 1: 1), 0 , 6 g of 10-palladium on actvirovain coal and hydrogen being passed in for 20 hours with intensive stirring. Then the catalyst is filtered off, the filtrate is evaporated. The residue is mixed with aqueous ethanol and evaporated. The operation is repeated several times. The residue is triturated with a mixture of ethanol - ether (1: 1) and filtered. Obtain 0.7 g (75% of theoretical) of methyl ester (Sar, Ааа®) -angiotensin 11, which is purified as described above. 0 The final product has the following Rpo, 23; , 5t; Characteristics: R | iO, 27. Amino Acid Analysis: His 0.97 (0, Arg 1.03 (1); Pro 1.06 (1); WAY, 03 (1) Me 0.98 (1); Tug 0.6 (1); Sar 1.0 (О The described octapeptide methyl esters of general formula are studied as antagonists of the natural hormone angiotensin 11. The antagonistic effect of new compounds of the general formula (.1) is examined on anesthetized cats. In the study, vagus nerves of animals are cut on both sides of the neck and after blocking of the nerve nodes are administered to animals hypertension (Clba) by infusion at a rate of 0.5 g / kg / min. After stabilization of the increased blood pressure in the animal od intravenously or subcutaneously test substance The decrease in blood pressure caused by the injection of a substance is measured in a physiological solution.The decrease in blood pressure is recorded in millimeters pTytHoro of the column / and as a percentage of the initial pressure value measured prior to the injection of the test substance. Compounds are understood to mean the time until a significant decrease in blood pressure (). For comparison, the data obtained using the known angiotensin 11-saralisin antagonist (1- (M-methylglycine) -5-1-valine, 8-alanine) -angiotensin 11) are given in those. same conditions. The results obtained are presented in the table. From the table it follows that the proposed compounds, when administered intravenously, significantly reduce blood pressure. Upon subcutaneous administration, methyl esters of octapeptides of the general formula (II also exhibits the ability to reduce experimentally induced increases in blood pressure. These compounds can be used in therapy as blood pressure lowering agents.
    Methyl ether (Sar, Thr (MeS) -angiotensin 11
    Methyl ether (OGly, Mev) -an
    12
    12
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING METHYL ETHERS OF OCTAPEPTIDES OF GENERAL FORMULA I
    X-Arg-VaP-Tyr-IPe-His-Fro-Y-OMe, where X-Sar, hydroxyacetyl;
    Y-lPe, Thr (Me), Thr, Ala,. characterized in that from a protected octapeptide methyl ester of the general formula P
    Z-Arg (NO 2 ) -VaP-Tyr (BzP) - | Re-:
    His (Dnp) -Y-OMe, where 2 is benzyloxycarbonyl;
    N02 nitro group;
    BzP is benzyl; *
    Opr - dinitrophenyl;
    X, Y have the indicated values, neg; they give a dinitrophenyl protective group by treatment with 2-mer-captoethanol, and then the remaining protective groups are removed by catalytic hydrogenolysis.
    SU 1041030
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1041030A3|1983-09-07|Process for preparing methyl esters of octapeptides
    AU675274B2|1997-01-30|Reduced size LHRH analogs
    DK148905B|1985-11-11|ANALOGY PROCEDURE FOR THE PREPARATION OF LH-RH ANALOGUE NONAPEPTID DERIVATIVES
    CA1065856A|1979-11-06|Derivatives of salmon calcitonin
    FI60553C|1982-02-10|FOERFARANDE FOER FRAMSTAELLNING AV OVULATIONSFRAMKALLANDE NONAPEPTIDAMIDDERIVAT
    US4003884A|1977-01-18|Peptides having LH-RH/FSH-RH activity
    EP0467279A2|1992-01-22|Polypeptides having c-AMP producing activity
    US4209442A|1980-06-24|Angiotensin II analogs and process for the preparation thereof
    US3770715A|1973-11-06|Acth active peptides having d serine as first aminoacid from n terminus and l ornithine as11 aminoacid
    CA1246059A|1988-12-06|Polypeptide-diesters, their production and use
    US3976770A|1976-08-24|Sar'-|Thr8 Angiotensin II as an angiotensin II antagonist
    CA1108124A|1981-09-01|ANTAGONISTIC ANGIOTENSION II ANALOGUES CONTAINING AN .alpha.-AMINOOXYACID IN THE POSITION-1
    GB1590645A|1981-06-03|Process for preparing hentriacontapeptide having activity in reducing blood calcium levels
    CA1249396A|1989-01-24|Partially retro-inverted decapeptide as a specificrenin inhibitor with high resistance to enzymatichydrolysis
    CA1039711A|1978-10-03|Angiotensin antagonist
    JP2563284B2|1996-12-11|Method for producing peptide by using perchlorate
    Suzuki et al.1969|Synthesis of every kinds of peptide fragments of bradykinin
    US3792033A|1974-02-12|Acth-type hormones whose first aminoacid is of d-configuration
    US3923770A|1975-12-02|{8 Me{hd 2{b Gly{hu 1{b , Ile{hu 8{b {9 -Anziotensin II as an angiotensin antagonist
    RU2010799C1|1994-04-15|Derivatives of pentapeptides
    US5215964A|1993-06-01|Peptides useful in regulating the immune and nervous systems
    EP0171270A2|1986-02-12|Process for the preparation of angiotensin-II analogues substituted in the 1-, 5- and 8-positions
    US3917579A|1975-11-04|Des-asp{hu 1{b -Ile{hu 8{b angiotensin II as a specific inhibitor for the release of aldosterone
    SCHOELKENS et al.1976|1, 8-Disubstituted Analogues of [Ile5] and [Val5] Angiotensin II: Difference in Potency and Specificity of Angiotensin II-Antagonistic Activity
    KONOPINSKA et al.1983|Synthesis and biological investigations of new tuftsin analogs with elongated peptide chain
    同族专利:
    公开号 | 公开日
    PH16791A|1984-02-28|
    FI72732C|1987-07-10|
    IL61923D0|1981-02-27|
    HU181009B|1983-05-30|
    US4388304A|1983-06-14|
    PL126240B1|1983-07-30|
    CS217987B2|1983-02-25|
    EP0034259B1|1985-06-12|
    AU541526B2|1985-01-10|
    IN153212B|1984-06-16|
    AU6627781A|1981-07-23|
    ES8205754A1|1982-07-01|
    YU9281A|1983-09-30|
    IL61923A|1984-01-31|
    DD156968A5|1982-10-06|
    DE3170906D1|1985-07-18|
    AT13740T|1985-06-15|
    PL229244A1|1981-10-30|
    FI810122L|1981-07-19|
    NO810150L|1981-07-20|
    NO155100B|1986-11-03|
    JPS56138155A|1981-10-28|
    YU41959B|1988-04-30|
    ES498582A0|1982-07-01|
    FI72732B|1987-03-31|
    CA1156222A|1983-11-01|
    EP0034259A1|1981-08-26|
    NO155100C|1987-02-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3907762A|1971-12-27|1975-09-23|Univ Sherbrooke|Angiotensin{hd II {B position 8 analogs|
    US3923770A|1974-05-10|1975-12-02|Francis Merlin Bumpus|{8 Me{hd 2{b Gly{hu 1{b , Ile{hu 8{b {9 -Anziotensin II as an angiotensin antagonist|
    US3923769A|1974-05-10|1975-12-02|Francis Merlin Bumpus|{8 N-Me-Ile{40 ,Ile{hu 8{b {9 -Angiotensin II as an angiotensin antagonist|
    US3925345A|1974-05-10|1975-12-09|Francis Merlin Bumpus|(sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist|
    US3975365A|1975-01-27|1976-08-17|G. D. Searle & Co.|Inhibitory octapeptides angiotensin II|
    US3976770A|1975-02-10|1976-08-24|Francis Merlin Bumpus|Sar'-Thr8 Angiotensin II as an angiotensin II antagonist|
    US3973006A|1975-02-21|1976-08-03|E. R. Squibb & Sons, Inc.|Peptide enzyme inhibitors of angiotensin I|
    HU177134B|1977-07-18|1981-07-28|Richter Gedeon Vegyeszet|Process for preparing angiotensin ii analogues containing alpha-hydroxy-acid in position 1 with angiotensin ii antagonist activity|
    HU177133B|1977-07-18|1981-07-28|Richter Gedeon Vegyeszet|Process for preparing angiotensin ii analogues containing alpha- amino-oxy-acid in position 1 with angiotensin ii antagonist activity|HU191961B|1984-08-02|1987-04-28|Richter Gedeon Vegyeszet|Process for producing 1,5 and 8 substituted peptides of angiotenzin-ii antagonistic activity|
    US5182264A|1986-03-07|1993-01-26|Schering Corporation|Angiotensin II receptor blockers as antiglaucoma agents|
    US4983402A|1989-02-24|1991-01-08|Clinical Technologies Associates, Inc.|Orally administerable ANF|
    US4976968A|1989-02-24|1990-12-11|Clinical Technologies Associates, Inc.|Anhydrous delivery systems for pharmacological agents|
    US5443841A|1992-06-15|1995-08-22|Emisphere Technologies, Inc.|Proteinoid microspheres and methods for preparation and use thereof|
    US6221367B1|1992-06-15|2001-04-24|Emisphere Technologies, Inc.|Active agent transport systems|
    US5714167A|1992-06-15|1998-02-03|Emisphere Technologies, Inc.|Active agent transport systems|
    US6099856A|1992-06-15|2000-08-08|Emisphere Technologies, Inc.|Active agent transport systems|
    US5811127A|1992-06-15|1998-09-22|Emisphere Technologies, Inc.|Desferrioxamine oral delivery system|
    US5447728A|1992-06-15|1995-09-05|Emisphere Technologies, Inc.|Desferrioxamine oral delivery system|
    US5578323A|1992-06-15|1996-11-26|Emisphere Technologies, Inc.|Proteinoid carriers and methods for preparation and use thereof|
    US5401516A|1992-12-21|1995-03-28|Emisphere Technologies, Inc.|Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof|
    US5958457A|1993-04-22|1999-09-28|Emisphere Technologies, Inc.|Compositions for the delivery of antigens|
    US5709861A|1993-04-22|1998-01-20|Emisphere Technologies, Inc.|Compositions for the delivery of antigens|
    US5643957A|1993-04-22|1997-07-01|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    IL109403D0|1993-04-22|1994-07-31|Emisphere Tech Inc|Oral drug delivery compositions and methods|
    US6461643B2|1993-04-22|2002-10-08|Emisphere Technologies, Inc.|Oral drug delivery compositions and methods|
    US5792451A|1994-03-02|1998-08-11|Emisphere Technologies, Inc.|Oral drug delivery compositions and methods|
    US5629020A|1994-04-22|1997-05-13|Emisphere Technologies, Inc.|Modified amino acids for drug delivery|
    US5541155A|1994-04-22|1996-07-30|Emisphere Technologies, Inc.|Acids and acid salts and their use in delivery systems|
    US5693338A|1994-09-29|1997-12-02|Emisphere Technologies, Inc.|Diketopiperazine-based delivery systems|
    US6331318B1|1994-09-30|2001-12-18|Emisphere Technologies Inc.|Carbon-substituted diketopiperazine delivery systems|
    US6090958A|1995-03-31|2000-07-18|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    CN1151836C|1995-03-31|2004-06-02|艾米斯菲尔技术有限公司|Compound and compositions for delivering active agents|
    US5965121A|1995-03-31|1999-10-12|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US5989539A|1995-03-31|1999-11-23|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US6001347A|1995-03-31|1999-12-14|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US5866536A|1995-03-31|1999-02-02|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US5650386A|1995-03-31|1997-07-22|Emisphere Technologies, Inc.|Compositions for oral delivery of active agents|
    US5820881A|1995-04-28|1998-10-13|Emisphere Technologies, Inc.|Microspheres of diamide-dicarboxylic acids|
    US5667806A|1995-06-07|1997-09-16|Emisphere Technologies, Inc.|Spray drying method and apparatus|
    US6051258A|1995-06-07|2000-04-18|Emisphere Technologies, Inc.|Proteinoid emulsions and methods for preparation and use thereof|
    US5824345A|1995-06-07|1998-10-20|Emisphere Technologies, Inc.|Fragrances and flavorants|
    US5750147A|1995-06-07|1998-05-12|Emisphere Technologies, Inc.|Method of solubilizing and encapsulating itraconazole|
    GB2320248B|1995-09-11|1999-04-14|Emisphere Tech Inc|Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones|
    SI9720025A|1996-03-29|1999-08-31|Emishphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    WO1997047288A1|1996-06-14|1997-12-18|Emisphere Technologies, Inc.|Microencapsulated fragrances and method for preparation|
    US5879681A|1997-02-07|1999-03-09|Emisphere Technolgies Inc.|Compounds and compositions for delivering active agents|
    US6358504B1|1997-02-07|2002-03-19|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US5939381A|1997-02-07|1999-08-17|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US5876710A|1997-02-07|1999-03-02|Emisphere Technologies Inc.|Compounds and compositions for delivering active agents|
    US5804688A|1997-02-07|1998-09-08|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US6060513A|1997-02-07|2000-05-09|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US5990166A|1997-02-07|1999-11-23|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US6313088B1|1997-02-07|2001-11-06|Emisphere Technologies, Inc.|8-[ amino]-octanoic acid compositions for delivering active agents|
    US5863944A|1997-04-30|1999-01-26|Emisphere Technologies, Inc.|Compounds and compositions for delivering active agents|
    US5962710A|1997-05-09|1999-10-05|Emisphere Technologies, Inc.|Method of preparing salicyloylamino acids|
    IL140993D0|2000-05-15|2002-02-10|Bayer Ag|Trypsin substrate and diagnostic device, and method of using same|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    HU8080101A|HU181009B|1980-01-18|1980-01-18|Process for preparing angiotensin-ii analogues with antagonictic activity containing in position 1 sarcosyl,hydroxyacetyl or l-alpha-aminoxy-propionyl group and in positiona 8 esteric group|
    [返回顶部]